Abstract | OBJECTIVE: MATERIAL AND METHODS: RESULTS AND CONCLUSION: The long-term combined therapy with the addition of D-, L-gopantenic acid ( pantogam activ) allowed to achieve clinical improvement earlier (on 8th week in the main group versus 16th week in the control group). The frequency and severity of secondary negative symptoms associated with antipsychotic therapy were decreased as well. The high efficacy and tolerability of the combined therapy allow to improve quality of life in patients with schizophrenia and their compliance to treatment as well as to reduce costs of medical care.
|
Authors | V E Medvedev, V I Frolova, E V Gushanskaya, A U Ter-Israelyan |
Journal | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
(Zh Nevrol Psikhiatr Im S S Korsakova)
Vol. 115
Issue 8
Pg. 28-34
( 2015)
ISSN: 1997-7298 [Print] Russia (Federation) |
PMID | 26356612
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- GABA Agents
- pantogab
- Pantothenic Acid
- gamma-Aminobutyric Acid
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Cognition
- Female
- GABA Agents
(administration & dosage, therapeutic use)
- Humans
- Male
- Pantothenic Acid
(administration & dosage, analogs & derivatives, therapeutic use)
- Quality of Life
- Schizophrenia
(drug therapy)
- Treatment Outcome
- gamma-Aminobutyric Acid
(administration & dosage, analogs & derivatives, therapeutic use)
|